| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Bosutinib |
| Brand | Bosulif® |
| Indication | Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. |
| Assessment Process | |
| Rapid review commissioned | 09/08/2013 |
| Rapid review completed | 18/09/2013 |
| Rapid review outcome | At the current price a full HTA would be required. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
